BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

201 related articles for article (PubMed ID: 16365597)

  • 1. Target antigen expression on a professional antigen-presenting cell induces superior proliferative antitumor T-cell responses via chimeric T-cell receptors.
    Rossig C; Bär A; Pscherer S; Altvater B; Pule M; Rooney CM; Brenner MK; Jürgens H; Vormoor J
    J Immunother; 2006; 29(1):21-31. PubMed ID: 16365597
    [TBL] [Abstract][Full Text] [Related]  

  • 2. CD28 co-stimulation via tumour-specific chimaeric receptors induces an incomplete activation response in Epstein-Barr virus-specific effector memory T cells.
    Altvater B; Pscherer S; Landmeier S; Niggemeier V; Juergens H; Vormoor J; Rossig C
    Clin Exp Immunol; 2006 Jun; 144(3):447-57. PubMed ID: 16734614
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Epstein-Barr virus-specific human T lymphocytes expressing antitumor chimeric T-cell receptors: potential for improved immunotherapy.
    Rossig C; Bollard CM; Nuchtern JG; Rooney CM; Brenner MK
    Blood; 2002 Mar; 99(6):2009-16. PubMed ID: 11877273
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Epstein Barr virus specific cytotoxic T lymphocytes expressing the anti-CD30zeta artificial chimeric T-cell receptor for immunotherapy of Hodgkin disease.
    Savoldo B; Rooney CM; Di Stasi A; Abken H; Hombach A; Foster AE; Zhang L; Heslop HE; Brenner MK; Dotti G
    Blood; 2007 Oct; 110(7):2620-30. PubMed ID: 17507664
    [TBL] [Abstract][Full Text] [Related]  

  • 5. In vitro comparison of three different chimeric receptor-modified effector T-cell populations for leukemia cell therapy.
    Pizzitola I; Agostoni V; Cribioli E; Pule M; Rousseau R; Finney H; Lawson A; Biondi A; Biagi E; Marin V
    J Immunother; 2011; 34(6):469-79. PubMed ID: 21654519
    [TBL] [Abstract][Full Text] [Related]  

  • 6. PiggyBac-mediated cancer immunotherapy using EBV-specific cytotoxic T-cells expressing HER2-specific chimeric antigen receptor.
    Nakazawa Y; Huye LE; Salsman VS; Leen AM; Ahmed N; Rollins L; Dotti G; Gottschalk SM; Wilson MH; Rooney CM
    Mol Ther; 2011 Dec; 19(12):2133-43. PubMed ID: 21772253
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Induction of minor histocompatibility antigen-specific T-helper but not T-cytotoxic response is dependent on the source of antigen-presenting cell.
    van Els CA; Bakker A; van Rood JJ; Goulmy E
    Hum Immunol; 1990 May; 28(1):39-50. PubMed ID: 2160446
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ex vivo generation of cytotoxic T lymphocytes specific for one or two distinct viruses for the prophylaxis of patients receiving an allogeneic bone marrow transplant.
    Regn S; Raffegerst S; Chen X; Schendel D; Kolb HJ; Roskrow M
    Bone Marrow Transplant; 2001 Jan; 27(1):53-64. PubMed ID: 11244438
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Enhanced antilymphoma efficacy of CD19-redirected influenza MP1-specific CTLs by cotransfer of T cells modified to present influenza MP1.
    Cooper LJ; Al-Kadhimi Z; Serrano LM; Pfeiffer T; Olivares S; Castro A; Chang WC; Gonzalez S; Smith D; Forman SJ; Jensen MC
    Blood; 2005 Feb; 105(4):1622-31. PubMed ID: 15507526
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Function of Novel Anti-CD19 Chimeric Antigen Receptors with Human Variable Regions Is Affected by Hinge and Transmembrane Domains.
    Alabanza L; Pegues M; Geldres C; Shi V; Wiltzius JJW; Sievers SA; Yang S; Kochenderfer JN
    Mol Ther; 2017 Nov; 25(11):2452-2465. PubMed ID: 28807568
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Stimulation with allogeneic Epstein-Barr virus-transformed lymphoblastoid cell lines generates HLA class I-specific CTLs with different target cell avidity.
    Torsteinsdottir S; Cuomo L; Klein E; Masucci MG
    Cell Immunol; 1991 Oct; 137(2):501-13. PubMed ID: 1654213
    [TBL] [Abstract][Full Text] [Related]  

  • 12. CD28 costimulation provided through a CD19-specific chimeric antigen receptor enhances in vivo persistence and antitumor efficacy of adoptively transferred T cells.
    Kowolik CM; Topp MS; Gonzalez S; Pfeiffer T; Olivares S; Gonzalez N; Smith DD; Forman SJ; Jensen MC; Cooper LJ
    Cancer Res; 2006 Nov; 66(22):10995-1004. PubMed ID: 17108138
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characteristics of human EBV-specific cytotoxic T lymphocytes utilized for adoptive immunotherapy of EBV-induced lymphoproliferations in xenografted SCID mice.
    Lacerda JF; O'Reilly RJ
    Ann Oncol; 1997; 8 Suppl 2():137-40. PubMed ID: 9209657
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Epstein-Barr virus-transformed B-cells as efficient antigen presenting cells to propagate Aspergillus-specific cytotoxic T-lymphocytes.
    Ramadan G
    Egypt J Immunol; 2008; 15(1):145-57. PubMed ID: 20306679
    [TBL] [Abstract][Full Text] [Related]  

  • 15. At the Bench: Chimeric antigen receptor (CAR) T cell therapy for the treatment of B cell malignancies.
    Daniyan AF; Brentjens RJ
    J Leukoc Biol; 2016 Dec; 100(6):1255-1264. PubMed ID: 27789538
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Construction of a new anti-CD19 chimeric antigen receptor and the anti-leukemia function study of the transduced T cells.
    An N; Tao Z; Li S; Xing H; Tang K; Tian Z; Rao Q; Wang M; Wang J
    Oncotarget; 2016 Mar; 7(9):10638-49. PubMed ID: 26840021
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Broadening Specificity and Enhancing Cytotoxicity of Adoptive T Cells for Nasopharyngeal Carcinoma Immunotherapy.
    Faè DA; Martorelli D; Mastorci K; Muraro E; Dal Col J; Franchin G; Barzan L; Comaro E; Vaccher E; Rosato A; Dolcetti R
    Cancer Immunol Res; 2016 May; 4(5):431-40. PubMed ID: 27009165
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Virus-specific T cells engineered to coexpress tumor-specific receptors: persistence and antitumor activity in individuals with neuroblastoma.
    Pule MA; Savoldo B; Myers GD; Rossig C; Russell HV; Dotti G; Huls MH; Liu E; Gee AP; Mei Z; Yvon E; Weiss HL; Liu H; Rooney CM; Heslop HE; Brenner MK
    Nat Med; 2008 Nov; 14(11):1264-70. PubMed ID: 18978797
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High Cytotoxic Efficiency of Lentivirally and Alpharetrovirally Engineered CD19-Specific Chimeric Antigen Receptor Natural Killer Cells Against Acute Lymphoblastic Leukemia.
    Müller S; Bexte T; Gebel V; Kalensee F; Stolzenberg E; Hartmann J; Koehl U; Schambach A; Wels WS; Modlich U; Ullrich E
    Front Immunol; 2019; 10():3123. PubMed ID: 32117200
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Human Epstein-Barr virus (EBV)-specific cytotoxic T lymphocytes home preferentially to and induce selective regressions of autologous EBV-induced B cell lymphoproliferations in xenografted C.B-17 scid/scid mice.
    Lacerda JF; Ladanyi M; Louie DC; Fernandez JM; Papadopoulos EB; O'Reilly RJ
    J Exp Med; 1996 Mar; 183(3):1215-28. PubMed ID: 8642263
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.